Although the entry form has a three-part question on HIV testing and status, the data it yields are inadequate for surveillance purposes. About half the prescribers do not complete the questions (completion of all items is not enforced) and the information is based on patient self-report so its reliability is uncertain. A Review of Methadone Treatment' form which is also due every six months includes questions on HW status but compliance by doctors in completing this form is poor.
11W testing pracLices
There is a variety of screening practices, which range from arranging HtV tests at the methadone clinic for virtually all patients to always referring patients elsewhere (such as clinics specialising in AIDS/HIV) for HIV-test-related action. Neither the Health Department nor DODO has collected systematic data on individual prescribers' or clinics' HIV screening practices.
STUDY OBJECTIVES
Our chief objective was to develop and trial a new procedure for directly obtaining accurate, timely HIV surveillance data from methadone prescribers. The main data of interest were:
HIV sero-conversion prevalence rates among methadone patients; and, HIV sero-conversion incidence rates among methadone patients.
The data would also provide:
Baseline data on H[V testing status (when and where previously tested) for new patients; Information on HIV testing practices of methadone prescribers; and, Opportunities to explore relationships between HW status and selected patient characteristics't.
METHODS
Ten private prescribers and three public clinics agreed to complete four items of information on patients who had had an HIV test. Prescribers were selected for this study because they were likely to be interested and/or Co. operative. Participation was voluntary and of those approached, only one refused to take part. Some prescribers offered to take part without being approached. We discussed the study with the individual prescribers to confirm their co-operation and commitment.
We supplied specially designed data collection forms on which the prescribers recorded, for each patient who had an HIV test, the month and year of the most recent test, where the test took place, the result and whether the result was verified by the prescriber or based solely on the patient's self-report. 
RESULTS

Prescriber response
Of the 13 prescribers who agreed to participate, 10 supplied the information. These 10 prescribers were treating around one-quarter of the patients in the program. Their patients were similar to other patients on the program in terms of sex, age, marital status and duration of narcotic use and dependence.
Most prescribers had to be followed up, some many times, before any forms were returned. The main reasons given for slow completion of forms were a lack of time (especially for those without secretarial support) and having to identify patients by number rather than by name.
HIV testing practices
The private prescribers in this study had incorporated routine HIlT testing into their entry procedures and were about to begin or had already started regular retesting for patients in treatment. In the public clinic, procedures ranged from almost complete testing at the clinic to complete referral. Private patients, therefore,
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were much more likely to have been tested and those who were tested during September-November 1989 were usually tested around the same time either by the prescriber or at a clinic with which that prescriber was associated. As with the total population of methadone patients, I-il V-related information for patients in this study was usually missing from their entry assessment forms (for example, HIV testing status had not been recorded for 64 per cent of the patients).
Data quality
HIV test results
The prescribers indicated that 467 (35 per cent) of their patients had had an HW test. Of these, 9 (2 per cent) were HIV-positive. All positive results were verified by the prescriber. This low HIV-positive rate is consistent with four recent studies of IVDU in western Sydney, in each of which fewer than 1 per cent of patients were found to be HW-positive. Considerable follow-up was needed to obtain voluntarily supplied data from this group of cooperative prescribers. If a system of compulsory supply of HIV testing data were to be introduced, the important issue of how to enforce this would need to be addressed. For example, prescribers tend to comply with the six-monthly prescription update because Departmental authority for them to continue to prescribe methadone is contingent upon it, whereas they leave many sections of the treatment assessment form unanswered because no such consequence applies. fl
The volume and quality of the data available from each prescriber will be related to the HIV testing practices of that prescriber. Those who do not directly arrange testing for their patients have difficulty supplying accurate, verified data, even of the most basic kind (date, place, result of
E6
HIV test), since the confidentiality of HIV test results is protected by legislation. Accurate, updated information on individual prescribers' HIV testing practices is needed.
The Methadone Program's policy on HIV testing allows prescribers the full range from no testing or referrals whatsoever to the equivalent of comprehensive regular screening. The policy needs clarification.
Where prescribers have access to HIV testing information about their clients (for example, because they arrange regular HIV testing), the data supplied are likely to be more timely, accurate and complete than has been available from entry assessment forms.
The accuracy and comprehensiveness of data collected would be improved if prescribers were encouraged to arrange HIV testing, for example by making resources available to assist them with testing, coimselling and/or data transcription.
HIV surveillance data obtained from prescribers can be successfully linked with patient characteristics on the Methadone Stats Unit database via the patients' unique identifying numbers.
Introduction of uniform and reliable HIV antibody screening procedures in the Methadone Program would assist efforts to gain a clearer picture of the prevalence and incidence of HIV in the patient population. 
EDITORIAL NoTE
Following on from this study, a panel of NSW AIDS and drug researchers, clinicians and administrators was formed to draft strategies to improve the monitoring of H1V infection in IVDUs. 
